Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Cyclacel Pharmaceuticals ( (CYCC) ).
On June 30, 2025, Cyclacel Pharmaceuticals held its Annual Meeting where shareholders re-elected five directors for a three-year term and approved an amendment to the 2018 Equity Incentive Plan, increasing available shares by 4,281,987. Additionally, the executive compensation package was approved by an advisory vote, reflecting strong shareholder support for the company’s leadership and strategic direction.
The most recent analyst rating on (CYCC) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Cyclacel Pharmaceuticals stock, see the CYCC Stock Forecast page.
Spark’s Take on CYCC Stock
According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on CYCC stock, click here.
More about Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for cancer treatment.
Average Trading Volume: 1,455,507
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.86M
See more data about CYCC stock on TipRanks’ Stock Analysis page.